中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.017 seconds)

    Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof
    1.
    发明授权
    Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof 有权

    公开(公告)号：US11249081B2

    公开(公告)日：2022-02-15

    申请号：US16329751

    申请日：2017-08-31

    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

    Inventor： Florent Ginhoux ,  Chi Ee Peter See

    IPC: G01N33/569 ,  A61K35/15 ,  C07K16/28

    Abstract: Biomarkers for the detection and identification of a precursor of conventional dendritic cell (cDC) (pre-DC) and its cell subsets (pre-cDC1 or pre-cDC2), are defined, which include CD169, CD327, AXL, CD271, CD324 and combinations thereof for detecting pre-DCs. Methods for detecting a disease or condition, prognosis of an existing disease or condition comprising determining the number of pre-DC cells in sample from a subject as compared to control, as well as methods of treating a patient comprising administration of antibodies against CD169, CD327, AXL, CD271, CD324 and combinations thereof are also disclosed. In addition, an immunogenic composition comprising one or more binding molecules specific for one or more biomarkers or antigen of a target disease and/or one or more cells selected from the group consisting of early pre-DC, pre-cDC1 and pre-cDC2 are also disclosed for eliciting an immune response against an infectious disease or cancer.

    IN VIVO DENDRITIC CELL THERAPEUTIC ADJUVANT
    2.
    发明申请
    IN VIVO DENDRITIC CELL THERAPEUTIC ADJUVANT 审中-公开
    在体内细胞治疗药物中

    公开(公告)号：US20140004079A1

    公开(公告)日：2014-01-02

    申请号：US13924479

    申请日：2013-06-21

    Applicant: Agency for Science, Technology and Research

    Inventor： Adam Joseph GEHRING ,  Antonio Bertoletti ,  Florent Ginhoux

    IPC: A61K39/00

    CPC classification number: A61K39/0005 ,  A61K38/1841 ,  A61K38/191 ,  A61K38/193 ,  A61K38/195 ,  A61K38/20 ,  A61K38/212 ,  A61K38/217 ,  Y02A50/411 ,  A61K2300/00

    Abstract: Disclosed is a method of eliciting an immune response to an antigen present endogenously in a mammal. The method may comprise administering to the mammal a composition comprising at least one immunomodulator for inducing cell differentiation and or antigen-presenting function of antigen-presenting cell precursor. The antigen-presenting cell precursor may have taken up the antigen. Also disclosed are a composition for use in the method, an adjuvant comprising the composition, the use of the composition and the immunomodulator as described herein.

    Abstract translation: 公开了一种引起对哺乳动物内源性存在的抗原的免疫应答的方法。 该方法可以包括向哺乳动物施用包含至少一种用于诱导抗原呈递细胞前体的细胞分化和/或抗原呈递功能的免疫调节剂的组合物。 抗原呈递细胞前体可能已经吸收抗原。 还公开了用于该方法的组合物，包含组合物的佐剂，本文所述的组合物和免疫调节剂的用途。

    Neutrophil Progenitors and Related Methods and Uses
    5.
    发明公开
    Neutrophil Progenitors and Related Methods and Uses 审中-公开

    公开(公告)号：US20230213513A1

    公开(公告)日：2023-07-06

    申请号：US18000559

    申请日：2021-06-11

    Applicant: Agency for Science, Technology and Research

    Inventor： Lai Guan Ng ,  Immanuel Weng Han Kwok ,  De Li Leonard Tan ,  Florent Ginhoux

    IPC: G01N33/569

    CPC classification number: G01N33/56972 ,  G01N2333/705

    Abstract: There is provided a method of identifying a neutrophil progenitor, the method comprising: determining an expression of at least one biomarker selected from the group consisting of: CD71, LOX-1, CD164, CD112, CD181, TACSTD2, CD11b and CD49d in a cell. In various embodiments, the cell is identified as a neutrophil progenitor when it is determined to have at least one of the following expression profiles: CD71hi/+, LOX-1int/lo/−, CD164hi/+, CD112hi/+, CD181int/lo/−, TACSTD2hi/+, CD11blo/− and/or CD49dint/hi/+. Also disclosed are a method of sorting and/or separating neutrophil progenitors from a cell population, a composition that is enriched in neutrophil progenitors and related uses and methods.

    Differentiation of pluripotent cells into microglial cells expressing IBA-1
    6.
    发明授权
    Differentiation of pluripotent cells into microglial cells expressing IBA-1 有权

    公开(公告)号：US11618886B2

    公开(公告)日：2023-04-04

    申请号：US16916096

    申请日：2020-06-29

    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

    Inventor： Hwei-In Shawn Lim ,  Tara Huber ,  Florent Ginhoux

    IPC: C12N5/00 ,  C12N5/0786 ,  A61K35/15 ,  G01N33/50

    Abstract: The present invention relates to a method of culturing primitive macrophages from stem cells. Specifically, the method comprises contacting and incubating stem cells with a serum-free culture media comprising a GSK3 inhibitor to differentiate stem cells into cell of the mesoderm lineage, contacting and incubating cells of the mesoderm lineage with a culture media comprising DKK1 to differentiate the cells into the hematopoietic lineage, maturing the cells of the hematopoietic lineage and contacting and incubating these cells with a culture media comprising M-CSF to drive differentiation into primitive-like macrophages. The invention also relates to a primitive-like macrophage, use of the primitive-like macrophage and a kit when used in the method of the invention.

    Characterising Macrophages and Methods Thereof
    7.
    发明公开
    Characterising Macrophages and Methods Thereof 审中-公开

    公开(公告)号：US20240247317A1

    公开(公告)日：2024-07-25

    申请号：US18040066

    申请日：2021-08-04

    Applicant: Agency for Science, Technology and Research

    Inventor： Camille Bleriot ,  Florent Ginhoux ,  Ankur Sharma

    IPC: C12Q1/6886 ,  C12Q1/6874 ,  C12Q1/6881

    CPC classification number: C12Q1/6886 ,  C12Q1/6881 ,  C12Q1/6874 ,  C12Q2600/158

    Abstract: There is provided a method of characterising a macrophage in a tissue of a subject, wherein the method comprises determining an expression of one or more biomarkers in the macrophage, wherein the one or more biomarkers is selected from the group consisting of Folr2, SerpinaSi, Nid2, Slc27a6, SemaSa, Cdh13, Bcl6b, C6, Klf15, Marco, Cd209d, Tshz3, Bmpr1a, Tln2, Coro2b, Ackr2, 1110046J04Rik, Pcdhac2, Gm2253, Vsig4, Phactrt, NpM, CpneS, Angptl7, Gm26714, Auts2, Cxcl13, Sgce, 2900052N01 Rik, Cd209b, Timd4, Cd209g, Mrd (CD206), Spp1, Il22ra2, Gm24112, Gm23010, Ighv7-1, Gm23628, Gm24620, Gm23058, Arhgef37, Gad1-ps, Gm26397, Ighv2-5, Chil3, Mir1934, 1810012K08Rik, Ighv1-59, Gm14119, Gm19620 and Snord71. In one embodiment, the macrophage can be an embryo-derived macrophage and/or a long-lived tissue resident macrophage. In another embodiment, the macrophage can be a monocyte-derived macrophage. Also disclosed are methods of diagnosing a disease in a subject, methods of treating a disease, and kits for use thereof relating to a macrophage determined to express one or more of the said biomarkers.

    Method of Identifying Pro-Inflammatory Dendritic Cells
    8.
    发明公开
    Method of Identifying Pro-Inflammatory Dendritic Cells 审中-公开

    公开(公告)号：US20230184762A1

    公开(公告)日：2023-06-15

    申请号：US17596950

    申请日：2020-06-26

    Applicant: Agency for Science, Technology and Research

    Inventor： Florent Ginhoux ,  Charles Antoine Dutertre

    IPC: G01N33/569

    CPC classification number: G01N33/56972 ,  G01N2333/70596 ,  G01N2800/7095

    Abstract: There is provided a method of identifying pro-inflammatory dendritic cells, the method comprising: determining an expression of CD5, CD14 and/or CD163 in cells, wherein CD5−, CD14+ and/or GD163+ cells are identified as pro-inflammatory dendritic cells. Also disclosed is a method of characterising inflammation and/or inflammatory disease in a subject, the method comprising: determining a proportion of CD5−, CD14+ and/or GD163+ dendritic cells in the subject's sample, wherein the proportion positively correlates with the level of inflammation and/or the severity of inflammatory disease in the subject.

Patent Agency Ranking